Friday Jun 27
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa)...
Protalix BioTherapeutics, Inc. , announced today that new clinical data on ELELYSOTM will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel.
Easier access funded enzyme replacement therapy
PHARMAC is providing greater funded access to the expensive enzyme replacement therapy imiglucerase , mainly expanding its use in children.